Physician profile
Thomas Taylor
NPI 1215928494
$466.23
in general payments reported to CMS, 2019-2025
11 companies · $55.07 in 2025
The $55.07 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.91 · 2020: $97.98 · 2021: $48.38 · 2022: $137 · 2023: $31.99 · 2024: $50.57 · 2025: $55.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $137.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $117.42 | 2019-2025 | Orthovisc, Monovisc |
| Ferring Pharmaceuticals INC. | $86.11 | 2020-2021 | |
| Alafair Biosciences, INC. | $63.55 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $59.63 | 2024-2025 | |
| Bioventus LLC | $54.50 | 2022-2023 | Durolane |
| Ultragenyx Pharmaceutical INC. | $16.90 | 2020 | |
| Stryker Corporation | $14.63 | 2020 | |
| Daiichi Sankyo INC. | $14.48 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.36 | 2022 | |
| Smith+Nephew, INC. | $13.22 | 2022 | |
| Saluda Medical Americas, INC. | $12.43 | 2023 | Evoke Scs |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.